|
* Market Opportunity: 1 in 3 seniors die of Alzheimer's or another dementia, 5.7M/year in the US alone, no accurate diagnosis exists
* Technology: Diagnosis of dementia 8-10 years before it is apparent * Management Team: GE, Eli Lilly, Zimmer, JMP Securities |
Market Opportunity: Alzheimer's is the 6th leading cause of death in the U.S. 1 in 3* seniors die of Alzheimer's or another dementia. It kills more people than breast and prostate cancer combined. An estimated 5.7M Americans of all ages are living with Alzheimer’s dementia in 2018 (5.5M > 65 years old and approximately 200K < 65 years). In 2018, Alzheimer’s and other dementia will cost the nation $277B.* Early and accurate diagnosis could save up to $7.9T* in medical and care costs.
Technology: This Company has a diagnostic that can see the very beginning of Alzheimer’s disease starting 8-10 years before any dementia is apparent. The test is very easy and painless to do, and costs only $100-$200. The current standard is a PET with a radioactive marker that costs $3,000+ and involves toxic chemicals, and it cannot see the disease progression until later in its development. Most doctors don’t have easy access to a PET scanner. This novel early diagnosis allows a doctor to change medications, diet and exercise levels to delay the onset of the disease.
Currently, the Company has the world’s first/best demonstration of cerebral amyloid detection (vs blood tests). The Company has received strong positive feedback from academia and pharma at the Human Imaging Conference. The AAIC abstract recently submitted represents the best data on amyloid detection beside PET scan and CSF. Mayo Clinic and MGH have committed to deliver a large number of subjects at no cost to the Company.
Big pharma companies have over 25 new drugs in Phase 3 trials that will be able to treat the disease in the next few years. So this test for early detection will be even more valuable.
Management Team: The company is led by proven operators from GE, Eli Lilly, Zimmer and JMP Securities.
Ted Driscoll is a Board Observer; Michele Colucci is a Board Member
*Source: Alzheimer’s Association. 2018 Alzheimer’s Disease Facts and Figures
(1) Current investment from DigitalDX
Technology: This Company has a diagnostic that can see the very beginning of Alzheimer’s disease starting 8-10 years before any dementia is apparent. The test is very easy and painless to do, and costs only $100-$200. The current standard is a PET with a radioactive marker that costs $3,000+ and involves toxic chemicals, and it cannot see the disease progression until later in its development. Most doctors don’t have easy access to a PET scanner. This novel early diagnosis allows a doctor to change medications, diet and exercise levels to delay the onset of the disease.
Currently, the Company has the world’s first/best demonstration of cerebral amyloid detection (vs blood tests). The Company has received strong positive feedback from academia and pharma at the Human Imaging Conference. The AAIC abstract recently submitted represents the best data on amyloid detection beside PET scan and CSF. Mayo Clinic and MGH have committed to deliver a large number of subjects at no cost to the Company.
Big pharma companies have over 25 new drugs in Phase 3 trials that will be able to treat the disease in the next few years. So this test for early detection will be even more valuable.
Management Team: The company is led by proven operators from GE, Eli Lilly, Zimmer and JMP Securities.
Ted Driscoll is a Board Observer; Michele Colucci is a Board Member
*Source: Alzheimer’s Association. 2018 Alzheimer’s Disease Facts and Figures
(1) Current investment from DigitalDX